INTRADISCAL CONDOLIASE INJECTIONS: A NEW FRONTIER IN NON-SURGICAL DISC HERNIATION THERAPY
DOI:
https://doi.org/10.69723/njms.04.03.0608Keywords:
disc herniation, neurosurgery, Intradiscal Condoliase Injections, Non-Surgical Disc Herniation TherapyAbstract
The intradiscal condoliase injection stands out as the most biologically targeted and non surgical intervention currently available for lumbar disc herniation. It bridges a crucial therapeutic gap between conservative care and invasive surgery, offering durable pain relief with a single outpatient based treatment. Its mechanism is precise selectively degrading glycosaminoglycans in the nucleus pulposus and minimizing risk to the surrounding tissue. Beyonds symptoms control condoliase impact on quality of life, reduce recovery time and its cost-effectiveness make it especially promising in healthcare system seeking value based care. With consistent success rates of 70-78% in real world and clinical trial settings it presents an excellent option for well-selected patients. Nonetheless, long-term outcome data and broader internation adoption remain necessary to confirm its full therapeutic scope. As research advances and patient selection protocols improve, condoliase may reshape how clinicians approach intervertebral disc disorders and transforming pain management into precision enzymatic therapy.
References
Huang Z, Xu B, Liu Y, Chen H, Cai X, Zhang L, et al. The efficacy and safety of condoliase for lumbar disc herniation: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1151998.
https://doi.org/10.3389/fphar.2023.1151998
Kim KD, Ahadian F, Hassanzadeh H, Rivera JJ, Candido K, Gershon S, et al. A phase 3, randomized, double-blind, sham-controlled trial of SI-6603 (condoliase) in patients with radicular leg pain associated with lumbar disc herniation. Spine J. 2024.
https://doi.org/10.1016/j.spinee.2024.08.006
Nakajima H, Watanabe S, Honjoh K, Kubota A, Matsumine A. Indication and limitation of intradiscal condoliase injection for patients with lumbar disc herniation: literature review and meta-analysis. Spine Surg Relat Res. 2024;8(4):362–72.
https://doi.org/10.22603/ssrr.2023-0294
Nakajima H, Kubota A, Watanabe S, Honjoh K, Takeura N, Matsumine A. Pretreatment prognostic factors for intradiscal condoliase injection in patients with lumbar disc herniation: insights from clinical and MRI-based quantitative analysis. J Clin Med. 2025;14(5):1509.
https://doi.org/10.3390/jcm14051509
Oshita Y, Matsuyama D, Sakai D, Schol J, Shirasawa E, Emori H, et al. Multicenter retrospective analysis of intradiscal condoliase injection therapy for lumbar disc herniation. Medicina (Kaunas). 2022;58(9):1284.
https://doi.org/10.3390/medicina58091284
Suzuki N, Eguchi Y, Hirai T, Takahashi T, Takahashi Y, Watanabe K, et al. Outcome of intradiscal condoliase injection therapy for patients with recurrent lumbar disc herniation. Asian Spine J. 2024;18(3):550–9.
https://doi.org/10.31616/asj.2024.0042
Takaki S, Miyama H, Iwasaki M. Cost-effectiveness analysis of intradiscal condoliase injection vs surgical or conservative treatment for lumbar disc herniation. J Med Econ. 2023;26(1):233–42.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Wasif Ullah Khan, Mehr Un Nisa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purposes. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
.png)
